<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252277</url>
  </required_header>
  <id_info>
    <org_study_id>12349</org_study_id>
    <nct_id>NCT01252277</nct_id>
  </id_info>
  <brief_title>Breast Cancer Risk Biomarkers in Premenopausal Women</brief_title>
  <official_title>Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carol Fabian, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to gather information on how the prescription drug Lovaza™ which
      contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
      This drug is currently approved by the FDA for reducing blood levels of triglycerides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The central hypothesis is that 6 months of administration of high dose omega-3 fatty acid
      esters [eicosapentaenoic acid (EPA) 1860 mg, and docosahexaenoic acid (DHA) 1500 mg] daily in
      the form of a standard prescription strength dose of Lovaza™ (two 1 gram capsules twice
      daily) will have a favorable side effect profile and potential efficacy as demonstrated by
      favorable modulation of one or more blood and breast tissue risk biomarkers for breast cancer
      in premenopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day</measure>
    <time_frame>6 month visit</time_frame>
    <description>The proportion of subjects that complete an intervention of Lovaza™ 4 grams per day (~ 1800 mg EPA and 1500 mg DHA) administered for 6 months to premenopausal women under age 55.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modulation of the Risk Biomarker Masood Score</measure>
    <time_frame>6 month value compared to baseline value</time_frame>
    <description>Change in the semiquantitative cytology index score (Masood score) from baseline to end of study. Masood Score range 6 - 24; increasing values denote increasing cytologic abnormality. Thus, negative values for change reflect an improvement, i.e., less cytologic abnormality after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modulation of Ki-67 Expression</measure>
    <time_frame>6 month value compared to baseline value</time_frame>
    <description>Change (baseline to end of study) in percent of benign breast epithelial cells exhibiting immunostaining for Ki-67</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (DHA+EPA):AA Ratio for Phospholipids in Plasma.</measure>
    <time_frame>baseline to end of intervention (~6 months)</time_frame>
    <description>Change (from baseline to end of study) for the ratio derived from levels of DHA, EPA, and Arachadonic Acid (AA); measured as percent of total fatty acid content in the phospholipid compartment of plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life.</measure>
    <time_frame>duration of intervention, baseline to ~ 6 months</time_frame>
    <description>Change in score on Breast Cancer Prevention Trial (BCPT) Symptom Checklist. 43 symptoms, each scored as 0 to 4, are summed to provide a global score (range 0 to 172). Increasing score represents increasing problems with side effects. For change in score over period of intervention, a negative score indicates an improvement in quality of life while a positive score indicates increasing interference with daily activities due to worsening symptoms. Theoretically, the range of change could be -172 to +172.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lovaza™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza™ (two 1 gram capsules twice daily) for six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza™</intervention_name>
    <description>4 capsules daily for 6 months</description>
    <arm_group_label>Lovaza™</arm_group_label>
    <other_name>esters of EPA and DHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects must be premenopausal and between the ages of 25 and 54 and must have had a
             menstrual period within the past 12 months. Women who are not menstruating regularly
             due to use of certain types of contraceptives may be entered with restrictions. Their
             estrogen progesterone, and follicle stimulating hormone (FSH) levels must be
             documented at baseline random periareolar fine needle aspiration (RPFNA) and their off
             study RPFNA must take place at a similar portion of their cycle (high or low
             progesterone levels). In order to do this a serum progesterone will have to be
             obtained ~ 4 weeks before planned RPFNA and again 2 weeks later such that the RPFNA
             can be performed in the same phase of the &quot;cycle&quot; as baseline.

          -  Subjects must be at increased risk for breast cancer on the basis of at least one of
             the following criteria:

          -  A five-year Gail risk of ≥ 1.67% or three times the average risk for a woman of the
             same age using either the Surveillance Epidemiology and End Results (SEER,
             http://seer.cancer.gov) database or the NCI Breast Cancer Risk Assessment Tool
             (www.cancer.gov/bcrisktool)., or 10 yr Tyrer-Cuzick risk twice that of the population
             risk as listed in model, or RPFNA atypia

          -  BMI &lt;40 Kg/m3

          -  A first degree relative with breast cancer under the age of 60 or multiple second
             degree relatives with breast cancer.

          -  Multiple prior biopsies or at least one prior biopsy exhibiting atypical hyperplasia
             (AH), lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS).

          -  RPFNA evidence of hyperplasia with atypia within the last three years;

          -  Chest or neck radiation before age 30;

          -  Mammographic breast density by visual estimate equals or exceeds 50%.

          -  Subjects must be willing to continue the same hormonal milieu present at baseline
             throughout trial. If not using an oral, vaginal, or topical contraceptive, must be
             willing to actively use barrier methods of contraception to prevent pregnancy.

          -  Six months or more must have elapsed from completion of a prevention intervention
             trial (with exception of a weight reduction trial), ingestion of a selective estrogen
             receptor modulator (SERM) or aromatase inhibitor (AI) prior to baseline biomarker
             assessment.

          -  Subjects must be willing to undergo measurement of height, weight, and BMI and undergo
             body composite analysis (DEXA) at initiation and conclusion of intervention.

          -  Subjects with a history of AH, LCIS, or ER-positive DCIS by diagnostic biopsy, must
             have been counseled about appropriate standard prevention therapies such as tamoxifen
             and are either not eligible or are not interested in standard prevention therapies.
             Women with DCIS must have had appropriate local therapy (lumpectomy plus radiation or
             mastectomy). If subject has had a DCIS, at least two months must have elapsed from
             surgery and/or radiation therapy to the involved breast. Only the contralateral
             (uninvolved breast) will be studied by RPFNA. The subject may not have had any
             radiation therapy to the contralateral breast to be studied

          -  Subjects &gt; 40 must have had a screening mammogram within 6 months of entering the
             interventional portion of the study and read as not suspicious for breast cancer or if
             suspicious must have completed all suggested tests including biopsy and found to have
             no evidence of cancer. Subjects of sufficient age and/or risk for a baseline mammogram
             must be willing to have an off-study mammogram performed 6 months after study entry.

          -  Subjects must have had an RPFNA of the breast within six months prior to entering the
             intervention portion of the study and be willing to have another RPFNA at ~6.5 months
             after starting Lovaza™.

          -  Tissue Eligibility: Subjects must have cytomorphologic evidence of hyperplasia with
             atypia or borderline atypia (Masood score 14 or higher). There must be ≥500 epithelial
             cells on the slide for cytomorphology and evidence of proliferation by Ki-67 staining.
             There must be sufficient reserved methanol- formalin-fixed material for real time
             quantitative polymerase chain reaction (RT-qPCR). Frozen tissue must also have been
             obtained for fatty acid analysis, reverse phase proteomics, adipokines and cytokines,
             and RT-qPCR.

          -  Subjects must be willing to undergo phlebotomy at baseline, and 6 months and 6.5
             months approximately 3 tablespoons of blood will be obtained at baseline, and 6 months
             and 6.5 months or 6 tablespoons if the subject decides to participate in the optional
             monocyte cytokine release assay .

          -  Subjects must produce a spot urine sample at baseline, 6 months and at study
             conclusion. Baseline urine sample will in part be used to document that subject is not
             pregnant.

          -  Subjects must be willing to complete questionnaires regarding diet and supplement use,
             quality of life, relevant family history, personal health and reproductive history and
             medications at initiation and conclusion of the intervention.

          -  Subjects must be willing to sign an informed consent for the entire study and separate
             consent for repeat RPFNA

        Exclusion Criteria

          -  Women that have had a metastatic malignancy of any kind.

          -  Women that have had prior invasive breast cancer, diagnosed or treated within the past
             five years.

          -  Women who are currently taking anticoagulants.

          -  Women who have breast implants.

          -  Women who have undergone change in their hormonal milieu in the past 6 months this
             includes pregnancy, lactation, or stopping or starting hormonal contraceptives..

          -  Women who have taken omega 3 fatty acid supplements within 3 weeks prior to their
             baseline RPFNA.

          -  Women who regularly take NSAIDS (&gt;7 tablets weekly).

        Inclusion of Women and Minorities

        -This study utilizes women at increased risk for breast cancer. Subjects recruited from an
        established cohort of women followed in the Breast Cancer Prevention Center. From previous
        trials we can expect 6% minority accrual which is similar to our hospital demographics.
        Males are not included due to the low absolute risk of breast cancer, and the difficulty of
        performing RPFNA on the male breast.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Fabian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>December 14, 2015</results_first_submitted>
  <results_first_submitted_qc>June 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2016</results_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Carol Fabian, MD</investigator_full_name>
    <investigator_title>Professor, Director Breast Cancer Prevention Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women at high risk for development of breast cancer, seen in the Breast Cancer Prevention Center at the University of Kansas Medical Center.
Recruitment December 2010 to August 2012</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lovaza™</title>
          <description>Lovaza™: 4 capsules (total of 1860 mg EPA + 1500 mg DHA) daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lovaza™</title>
          <description>Lovaza™ (two 1 gram capsules twice daily) for six months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gail 5-year Projected Probability of developing breast cancer</title>
          <units>Projected Probability, percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day</title>
        <description>The proportion of subjects that complete an intervention of Lovaza™ 4 grams per day (~ 1800 mg EPA and 1500 mg DHA) administered for 6 months to premenopausal women under age 55.</description>
        <time_frame>6 month visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza™</title>
            <description>Lovaza™: 4 capsules daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Subjects That Complete an Intervention of Lovaza™ 4 Grams Per Day</title>
          <description>The proportion of subjects that complete an intervention of Lovaza™ 4 grams per day (~ 1800 mg EPA and 1500 mg DHA) administered for 6 months to premenopausal women under age 55.</description>
          <units>proportion of enrolled participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modulation of the Risk Biomarker Masood Score</title>
        <description>Change in the semiquantitative cytology index score (Masood score) from baseline to end of study. Masood Score range 6 - 24; increasing values denote increasing cytologic abnormality. Thus, negative values for change reflect an improvement, i.e., less cytologic abnormality after intervention.</description>
        <time_frame>6 month value compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza™</title>
            <description>Lovaza™: 4 capsules (total of 1860 mg EPA + 1500 mg DHA) daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Modulation of the Risk Biomarker Masood Score</title>
          <description>Change in the semiquantitative cytology index score (Masood score) from baseline to end of study. Masood Score range 6 - 24; increasing values denote increasing cytologic abnormality. Thus, negative values for change reflect an improvement, i.e., less cytologic abnormality after intervention.</description>
          <units>change in units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance, p&lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modulation of Ki-67 Expression</title>
        <description>Change (baseline to end of study) in percent of benign breast epithelial cells exhibiting immunostaining for Ki-67</description>
        <time_frame>6 month value compared to baseline value</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lovaza™</title>
            <description>Lovaza™: 4 capsules (total of 1860 mg EPA + 1500 mg DHA) daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Modulation of Ki-67 Expression</title>
          <description>Change (baseline to end of study) in percent of benign breast epithelial cells exhibiting immunostaining for Ki-67</description>
          <units>Change in percent Ki-67 expression</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" lower_limit="-2.55" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in (DHA+EPA):AA Ratio for Phospholipids in Plasma.</title>
        <description>Change (from baseline to end of study) for the ratio derived from levels of DHA, EPA, and Arachadonic Acid (AA); measured as percent of total fatty acid content in the phospholipid compartment of plasma.</description>
        <time_frame>baseline to end of intervention (~6 months)</time_frame>
        <population>Subjects completing intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza™</title>
            <description>Lovaza™: 4 capsules (total of 1860 mg EPA + 1500 mg DHA) daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in (DHA+EPA):AA Ratio for Phospholipids in Plasma.</title>
          <description>Change (from baseline to end of study) for the ratio derived from levels of DHA, EPA, and Arachadonic Acid (AA); measured as percent of total fatty acid content in the phospholipid compartment of plasma.</description>
          <population>Subjects completing intervention</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.34" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life.</title>
        <description>Change in score on Breast Cancer Prevention Trial (BCPT) Symptom Checklist. 43 symptoms, each scored as 0 to 4, are summed to provide a global score (range 0 to 172). Increasing score represents increasing problems with side effects. For change in score over period of intervention, a negative score indicates an improvement in quality of life while a positive score indicates increasing interference with daily activities due to worsening symptoms. Theoretically, the range of change could be -172 to +172.</description>
        <time_frame>duration of intervention, baseline to ~ 6 months</time_frame>
        <population>Subjects completing intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Lovaza™</title>
            <description>Lovaza™: 4 capsules (total of 1860 mg EPA + 1500 mg DHA) daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life.</title>
          <description>Change in score on Breast Cancer Prevention Trial (BCPT) Symptom Checklist. 43 symptoms, each scored as 0 to 4, are summed to provide a global score (range 0 to 172). Increasing score represents increasing problems with side effects. For change in score over period of intervention, a negative score indicates an improvement in quality of life while a positive score indicates increasing interference with daily activities due to worsening symptoms. Theoretically, the range of change could be -172 to +172.</description>
          <population>Subjects completing intervention</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-2.25" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>No adjustment for multiple comparisons. A priori threshold for statistical significance, p&lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>duration of intervention, planned at 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lovaza™</title>
          <description>Lovaza™ (two 1 gram capsules twice daily) for six months
Lovaza™: 4 capsules daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAEv4</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>increased bilirubin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pains</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>early awakening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>short temper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>breast tenderness or sensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carol J. Fabian, M.D.</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-7791</phone>
      <email>cfabian@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

